Comparing Jakafi vs Ruxolitinib
| Jakafi (ruxolitinib) | Ruxolitinib |
|
|---|
| Jakafi (ruxolitinib) | Ruxolitinib |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Myeloproliferative Disorders. Jakafi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Myeloproliferative Disorders. Ruxolitinib may also be used for purposes not listed in this medication guide. |
Related suggestions Polycythemia Vera
Myelofibrosis
Graft Versus Host Disease
|
|||||||
| More about Jakafi (ruxolitinib) | More about Ruxolitinib | ||||||||
| Ratings & Reviews | |||||||||
|
Jakafi has an average rating of 7.5 out of 10 from a total of 33 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 15% reported a negative effect. |
Ruxolitinib has an average rating of 7.4 out of 10 from a total of 42 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Jakafi side effects |
View all Ruxolitinib side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Jakafi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Jakafi | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
5.8 hours |
5.8 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 508 drugs are known to interact with Jakafi:
|
A total of 508 drugs are known to interact with Ruxolitinib:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
November 16, 2011 |
November 16, 2011 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.